STOCK TITAN

X4 Pharmaceuticals Inc - XFOR STOCK NEWS

Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.

X4 Pharmaceuticals Inc (XFOR) is a clinical-stage biopharmaceutical company pioneering oral therapies targeting the CXCR4 pathway to treat rare immunodeficiency disorders. This page provides a centralized hub for all official news, including press releases, clinical trial updates, and regulatory developments.

Investors and researchers will find timely updates on mavorixafor’s progress, partnership announcements, and financial disclosures. Content categories include clinical trial milestones, regulatory submissions, strategic collaborations, and earnings reports, ensuring comprehensive coverage of XFOR’s advancements.

Bookmark this page to stay informed about X4 Pharmaceuticals’ innovations in rare disease therapeutics, designed to address unmet medical needs through precision immunology.

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) will present a corporate overview at the Canaccord Genuity 42nd Annual Growth Conference in Boston, MA, on August 11, 2022, at 3:30 PM ET. The company focuses on developing novel CXCR4-targeted small molecule therapeutics for immune system diseases. A live webcast will be available on their website, with an archive accessible for 90 days post-event. Mavorixafor, their lead candidate, is under clinical trials for various conditions, including WHIM syndrome and chronic neutropenia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

X4 Pharmaceuticals reported its Q2 2022 financial results, revealing a net loss of $21.2 million, an increase from $19.6 million in Q2 2021. Cash and cash equivalents stood at $48.7 million as of June 30, 2022, bolstered by a recent PIPE financing raising approximately $56 million. The company anticipates significant milestones with data from its Phase 1b trial in chronic neutropenia expected in late September 2022, and pivotal Phase 3 results in WHIM syndrome expected in Q4 2022. X4 is now focusing its resources on chronic neutropenic disorders while pursuing partnerships for its oncology programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) has announced it will report its financial results for Q2 2022 on August 4, 2022. The company will also provide updates on notable business developments during a conference call at 8:30 a.m. ET, accessible via phone and a live webcast. X4's lead candidate, mavorixafor, is in a global Phase 3 trial for treating WHIM syndrome, a primary immunodeficiency disease. Mavorixafor shows promise in various conditions, including chronic neutropenic disorders and specific cancers. More details can be found on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) focuses on clinical candidate mavorixafor for chronic neutropenic disorders like WHIM syndrome. Key milestones include pivotal Phase 3 trial results and Phase 1b outcomes expected in 2022. A recent capital raise of $55 million, along with cost reductions, extends the company's cash runway into Q3 2023 and accelerates the mavorixafor NDA filing to early 2023. The company is streamlining resources and reducing operating expenses by approximately $25 million over two years, prioritizing mavorixafor while limiting oncology program advancements to potential partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.65%
Tags
none
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced on June 30, 2022, that its Compensation Committee granted inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. These options total 21,000 shares, with an exercise price of $0.96 per share, aligning with the closing price on that date. The options will vest over four years, and this issuance is in compliance with Nasdaq Listing Rule 5635(c)(4). X4 focuses on developing CXCR4-targeted small molecule therapies, including its lead candidate mavorixafor for immune system dysfunction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.58%
Tags
none
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced a private investment in public equity (PIPE) financing, agreeing to sell 50,925,365 shares of common stock and warrants, with expected gross proceeds of approximately $55 million. The financing is set to close around July 6, 2022. Concurrently, X4 amended its loan agreement with Hercules Capital to extend the interest-only period by up to 12 months, potentially reducing cash burn by $20 million. Funds will support clinical development of mavorixafor and general corporate purposes. The PIPE includes participation from several institutional investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.77%
Tags
none
Rhea-AI Summary

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) announced it will present research data on its lead drug candidate, mavorixafor, at the European Hematology Association congress in Vienna, June 9-17, 2022. Mavorixafor is an oral CXCR4 antagonist undergoing clinical trials for WHIM syndrome, chronic neutropenia, and Waldenström’s macroglobulinemia. Key findings include 17 new CXCR4 genetic variants related to WHIM, a new cell-based model for studying WHIM, and evidence of mavorixafor’s potential in enhancing B-cell therapies for WM.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
conferences
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) reported its Q1 2022 financial results, highlighting a net loss of $22 million, up from $18.7 million in Q1 2021. Cash and equivalents stood at $67.7 million, sufficient to fund operations through Q4 2022. The company anticipates top-line data from its pivotal 4WHIM Phase 3 trial for WHIM syndrome by year-end, alongside ongoing updates from a chronic neutropenia Phase 1b study and a fully enrolled Waldenström's Macroglobulinemia Phase 1b study. R&D expenses increased to $14.1 million, influenced by ongoing trials and initiatives to enhance disease awareness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
-
Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) will announce its first quarter financial results for the period ending March 31, 2022, on May 12, 2022. The company will also share business highlights during a conference call at 8:30 a.m. ET on the same day. Investors can join the call by dialing (866) 721-7655 in the U.S. or (409) 216-0009 internationally. X4’s lead candidate, mavorixafor, is being developed to treat immune system diseases, with ongoing clinical trials demonstrating its potential efficacy in conditions such as WHIM syndrome and certain cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
Rhea-AI Summary

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. On April 29, 2022, the Compensation Committee granted options to purchase 21,000 shares of common stock at an exercise price of $1.29 per share. The options will vest over four years, starting with 25% after 12 months. X4 focuses on developing novel therapies for immune system disorders, with its lead candidate mavorixafor in Phase 3 trials for WHIM syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
X4 Pharmaceuticals Inc

Nasdaq:XFOR

XFOR Rankings

XFOR Stock Data

33.13M
161.09M
1.27%
59.2%
5.56%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON